3674
J. J. Matasi et al. / Bioorg. Med. Chem. Lett. 15 (2005) 3670–3674
(c) Vu, C. B.; Pan, D.; Peng, B.; Sha, L.; Kumaravel, G.; Jin,
References and notes
X.; Phadke, D.; Engebr, T.; Huang, C.; Reilly, J.; Tam, S.;
Petter, R. C. Bioorg. Med. Chem. Lett. 2004, 14, 4831.
9. (a) Matasi, J. J.; Caldwell, J. P.; Hao, J.; Neustadt, B.;
Arik, L.; Foster, C. J.; Lachowicz, J.; Tulshian, D. Bioorg.
Med. Chem. Lett. 2005, 15, 1333; (b) Kiselgof, E.;
Tulshian, D.; Arik, L.; Zhang, H.; Fawzi, A. Bioorg.
Med. Chem. Lett. 2005, 15, 2119.
1. Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly,
J. W.; Harden, T. K.; Jacobson, K. A.; Legg, P.; Williams,
M. Pharmacol. Rev. 1994, 46, 143.
2. (a) Svenningsson, P.; Le Moine, C.; Fisone, G.; Fredholm,
B. B. Prog. Neurobiol 1999, 59, 355; (b) Schiffmann, S. N.;
Libert, F.; Vassart, G.; Dumont, J. E.; Vanderhaeghen, J.
J. Brain Res. 1990, 519, 333.
3. (a) Ochi, M.; Koga, K.; Kurokawa, M.; Kase, H.;
Nakamura, J.; Kuwana, Y. Neuroscience 2000, 100, 53;
(b) Mori, A.; Shindou, T.; Ichimura, M.; Nonka, H.;
Kase, H. J. Neurosci. 1996, 16, 605.
4. Kuwana, Y.; Shiozaki, S.; Kanda, T.; Kurokawa, M.;
Koga, K.; Ochi, M.; Ikeda, K.; Kase, H.; Jackson, M. J.;
Smith, L. A.; Pearce, R. K. B.; Jenner, P. Adv. Neurol. 1999,
80, 121.
5. (a) Shiozaki, S.; Ichikawa, S.; Nakamura, J.; Kitamura, S.;
Yamada, K.; Kuwana, Y. Psychopharmacology 1999, 147,
90; (b) Shiozaki, S.; Ichikawa, S.; Nakamura, J.; Kuwana,
Y. In Effects of Adenosine Receptors; Kase, H., Richardson,
P. J., Jenner, P., Eds.; Adenosine Receptors and ParkinsonÕs
Disease; Academic Press: New York, 1999, pp 193–210.
6. Aoyama, S.; Kase, H.; Borreli, E. J. Neurosci. 2000, 20,
5848.
10. (a) Dimroth, O. Ann 1909, 364, 183; (b) Dimroth, O. Ann
1927, 459, 39.
11. (a) Tsumuki, H.; Junichi, S.; Imma, H.; Nakamura, N.;
Nonaka, H.; Shiozki, S.; Ichikawa, S.; Kanda, T.; Kuw-
ana, Y.; Ichimura, M; Suzuki, F. U. S. Patent 6,222,035
B1; (b) Tsumuki, H.; Nakamura, N.; Shiozki, S.; Kuwana,
Y.; Ichimura, M.; Shimada. J. WO99/43678 A1.
12. Compound 1: 1H NMR (CDCl3, 400 MHz) d 7.66 (s, 1H),
7.55 (d, J = 8.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.14
(d, J = 3.4 Hz, 1H), 6.60 (br s, 2H), 6.53 (d, J = 3.4 Hz,
1H), 5.39 (t, J = 5.8 Hz, 1H), 4.51 (d, J = 5.8 Hz, 2H), 3.98
(s, 2H), 2.41 (s, 3H); 8g: 1H NMR (CDCl3, 400 MHz) d 8.0
(s, 1H), 7.86 (m, 1H), 7.62 (dd, 1H), 7.41–7.45 (m, 3H), 7.3
24 (d, 1H), 6.82–6.85 (m, 4H), 6.58 (dd, 1H), 6.28 (br s,
52H), 4.06 (t, 2H), 3.72 (t, 3H); 3.66 (s, 2H), 3.43 (s, 3H),
3.00–3.12 (m, 4H); 2.65–2.67 (m, 4H).
13. Adenosine A2A and A1 binding assays: [3H]SCH-58261
and [3H]DPCPX binding assays for adenosine A2A and A1
receptors, respectively, were performed as described
previously.14
7. Kanda, T.; Jackson, M. J.; Smith, L. A.; Pearce, R. K. B.;
Nakamura, J.; Kase, H.; Kuwana, Y.; Jenner, P. Exp.
Neurol. 2000, 162, 321.
14. (a) Dionisotti, S.; Ongini, E.; Zocchi, C.; Kull, B.; Arslan,
G.; Fredholm, B. B. Br. J. Pharmacol. 1997, 121, 353; (b)
Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, C.; Kull,
B.; Fredholm, B. B.; Lohse, M. J. Arch. Pharmacol. 1998,
357, 1.
8. (a) Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto,
G.; Monopoli, A.; Ongini, E.; Varani, K.; Borea, P. A. J.
Med. Chem. 2002, 45, 101; (b) Baraldi, P. G.; Cacciari, B.;
Spalluto, G.; Bergonzoni, M.; Dionosotti, S.; Ongini, E.;
Varani, K.; Borea, P. A. J. Med. Chem. 1998, 41, 2126;